Cue Biopharma (CUE) Short Interest Ratio & Short Volume $0.67 -0.04 (-5.34%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cue Biopharma Short Interest DataCue Biopharma (CUE) has a short interest of 867,100 shares. This marks a -1.85% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.1, indicating that it would take 5.1 days of the average trading volume of 426,011 shares to cover all short positions.Current Short Interest867,100 sharesPrevious Short Interest883,400 sharesChange Vs. Previous Month-1.85%Dollar Volume Sold Short$654,747.21Short Interest Ratio5.1 Days to CoverLast Record DateApril 30, 2025Outstanding Shares75,350,000 sharesPercentage of Shares Shorted1.15%Today's Trading Volume159,462 sharesAverage Trading Volume426,011 sharesToday's Volume Vs. Average37% Short Selling Cue Biopharma? Sign up to receive the latest short interest report for Cue Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCUE Short Interest Over TimeCUE Days to Cover Over TimeCUE Percentage of Float Shorted Over Time Cue Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2025867,100 shares $654,747.21 -1.9%N/A5.1 $0.76 4/15/2025883,400 shares $706,720.00 +3.7%1.6%4.5 $0.80 3/31/2025851,900 shares $776,080.90 -0.9%1.5%3.8 $0.91 3/15/2025859,900 shares $822,838.31 -10.0%1.5%3.3 $0.96 2/28/2025955,200 shares $1.17 million -6.4%1.7%3.2 $1.23 2/15/20251,020,000 shares $1.52 million -7.3%1.8%3.2 $1.49 1/31/20251,100,000 shares $1.60 million +1.9%N/A2.6 $1.45 1/15/20251,080,000 shares $1.40 million -16.9%N/A2.2 $1.30 12/31/20241,300,000 shares $1.42 million +20.4%N/A2.1 $1.09 12/15/20241,080,000 shares $1.02 million +8.0%N/A1.4 $0.94 Get the Latest News and Ratings for CUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. 11/30/20241,000,000 shares $1.22 million -6.5%N/A1.3 $1.22 11/15/20241,070,000 shares $1.33 million -39.9%N/A1.4 $1.25 10/31/20241,780,000 shares $2.87 million -8.7%N/A2.6 $1.61 10/15/20241,950,000 shares $2.18 million -48.7%N/A2.9 $1.12 9/30/20243,800,000 shares $2.88 million +6.7%N/A6.6 $0.76 9/15/20243,560,000 shares $2.10 million +3.8%N/A8.2 $0.59 8/31/20243,430,000 shares $2.48 million -6.3%N/A7.7 $0.72 8/15/20243,660,000 shares $2.17 million -9.2%N/A8.1 $0.59 7/31/20244,030,000 shares $3.37 million +8.3%N/A8.9 $0.84 7/15/20243,720,000 shares $3.46 million -21.5%N/A9.7 $0.93 6/30/20244,740,000 shares $5.88 million +5.6%N/A12.3 $1.24 6/15/20244,490,000 shares $6.11 million +3.2%N/A15.9 $1.36 5/31/20244,350,000 shares $7.09 million -5.2%N/A15.5 $1.63 5/15/20244,590,000 shares $7.53 million -7.5%N/A15.5 $1.64 4/30/20244,960,000 shares $9.42 million +3.8%N/A17.2 $1.90 4/15/20244,780,000 shares $7.62 million +13.8%N/A18.7 $1.60 3/31/20244,200,000 shares $7.94 million +1.9%N/A15.8 $1.89 3/15/20244,120,000 shares $8.53 million +3.8%N/A14.7 $2.07 2/29/20243,970,000 shares $8.24 million +4.2%N/A12.7 $2.08 2/15/20243,810,000 shares $8.95 million +5.8%N/A10.8 $2.35 1/31/20243,600,000 shares $9.50 million -1.4%N/A10.6 $2.64 1/15/20243,650,000 shares $10.91 million +6.7%N/A10.1 $2.99 12/31/20233,420,000 shares $9.03 million +5.2%N/A9.4 $2.64 12/15/20233,250,000 shares $9.20 million +8.3%N/A9.5 $2.83 11/30/20233,000,000 shares $7.50 million -1.0%N/A10 $2.50 11/15/20233,030,000 shares $7.21 million -2.6%N/A11.8 $2.38 10/31/20233,110,000 shares $6.53 million +19.6%N/A10.2 $2.10 10/15/20232,600,000 shares $5.33 million +2.4%N/A8.2 $2.05 9/30/20232,540,000 shares $5.84 million +2.8%N/A6.7 $2.30 9/15/20232,470,000 shares $6.32 million +1.2%N/A5.2 $2.56The Trump Dump is starting; Get out of stocks now? (Ad)The first 365 days of the Trump presidency… Will be the best time to get rich in American history.If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a 8/31/20232,440,000 shares $6.61 million -20.3%N/A5 $2.71 8/15/20233,060,000 shares $8.60 million -5.9%N/A6.2 $2.81 7/31/20233,250,000 shares $12.42 million +30.0%N/A7.1 $3.82 7/15/20232,500,000 shares $11.13 million +28.2%N/A5.5 $4.45 6/30/20231,950,000 shares $7.12 million +142.2%N/A5.4 $3.65 6/15/2023805,200 shares $3.12 million +10.1%N/A2.5 $3.87 5/31/2023731,600 shares $2.93 million +36.2%N/A3 $4.00 5/15/2023537,100 shares $2.39 million +1.0%N/A2.4 $4.45 4/30/2023531,900 shares $2.30 million -21.6%N/A2.8 $4.33 4/15/2023678,200 shares $2.36 million -10.5%N/A4.8 $3.48 3/31/2023757,900 shares $2.71 million +35.4%N/A5.5 $3.57 3/15/2023559,600 shares $1.75 million +21.8%N/A4.4 $3.12 2/28/2023459,500 shares $1.29 million +4.9%N/A4.3 $2.80 2/15/2023438,000 shares $1.47 million -12.7%N/A3.9 $3.35 1/31/2023501,900 shares $1.72 million -22.1%N/A3.9 $3.42 1/15/2023644,500 shares $2.24 million +8.8%N/A5 $3.48 12/30/2022592,200 shares $1.69 million -17.4%N/A4.4 $2.85 12/15/2022717,000 shares $2.03 million -5.7%N/A4.4 $2.83 11/30/2022759,900 shares $2.93 million -12.9%N/A4.8 $3.86 11/15/2022872,100 shares $3.30 million -29.7%N/A5.4 $3.78 10/31/20221,240,000 shares $3.30 million -10.8%N/A7.6 $2.66 10/15/20221,390,000 shares $3.57 million -6.1%N/A8.2 $2.57 9/30/20221,480,000 shares $3.30 million -12.4%N/A8.2 $2.23 9/15/20221,690,000 shares $5.53 million -12.9%N/A6 $3.27 8/31/20221,940,000 shares $5.70 million No ChangeN/A6.1 $2.94 8/15/20221,940,000 shares $6.48 million -11.0%N/A5.5 $3.34 7/31/20222,180,000 shares $5.93 million -0.5%N/A5.5 $2.72 7/15/20222,190,000 shares $5.76 million -3.5%N/A5.2 $2.63 6/30/20222,270,000 shares $5.65 million -36.6%N/A4.8 $2.49 6/15/20223,580,000 shares $11.06 million -8.7%11.6%7.2 $3.09 5/31/20223,920,000 shares $15.17 million -4.6%12.7%8.3 $3.87 5/15/20224,110,000 shares $14.84 million No Change13.2%8.5 $3.61 4/30/20224,110,000 shares $16.28 million +15.1%13.2%8.5 $3.96 4/15/20223,570,000 shares $16.21 million +6.6%11.5%6.5 $4.54 3/31/20223,350,000 shares $16.35 million -12.3%10.8%6.3 $4.88 3/15/20223,820,000 shares $16.85 million +8.5%N/A8 $4.41 2/28/20223,520,000 shares $20.42 million +1.4%11.5%8.3 $5.80 2/15/20223,470,000 shares $24.64 million +29.0%11.3%8.2 $7.10 1/31/20222,690,000 shares $19.88 million +18.0%8.8%6.5 $7.39 1/15/20222,280,000 shares $22.69 million +11.8%7.4%6.9 $9.95 12/31/20212,040,000 shares $23.07 million +10.9%6.7%6.4 $11.31 12/15/20211,840,000 shares $20.68 million +10.8%6.0%5.8 $11.24 11/30/20211,660,000 shares $20.35 million -8.8%5.4%5.3 $12.26 11/15/20211,820,000 shares $32.49 million -9.9%5.9%6.1 $17.85 10/29/20212,020,000 shares $24.66 million +3.1%6.8%7.8 $12.21 10/15/20211,960,000 shares $24.70 million -2.5%6.6%7.8 $12.60 9/30/20212,010,000 shares $29.29 million -15.6%6.8%8.6 $14.57 9/15/20212,380,000 shares $28.82 million -4.8%8.0%10.6 $12.11 8/31/20212,500,000 shares $29.98 million -2.0%8.4%12.7 $11.99 8/13/20212,550,000 shares $28.33 million -3.4%8.6%12.7 $11.11Watch This Robotics Demo Before July 23rd (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo… 7/30/20212,640,000 shares $27.51 million -2.2%8.9%6.2 $10.42 7/15/20212,700,000 shares $27.51 million -0.4%9.1%6.2 $10.19 6/30/20212,710,000 shares $31.57 million +1.5%9.1%6 $11.65 6/15/20212,670,000 shares $35.22 million -6.3%9.0%5.9 $13.19 5/28/20212,850,000 shares $40.87 million -5.3%9.6%6.1 $14.34 5/14/20213,010,000 shares $38.98 million +16.2%N/A6 $12.95 4/30/20212,590,000 shares $31.11 million -10.4%N/A5.3 $12.01 4/15/20212,890,000 shares $36.04 million -8.0%N/A9.3 $12.47 3/31/20213,140,000 shares $36.11 million +11.0%N/A10.1 $11.50 3/15/20212,830,000 shares $44.57 million +1.8%N/A8.5 $15.75 2/26/20212,780,000 shares $36.78 million +0.7%N/A8.8 $13.23 2/12/20212,760,000 shares $43.33 million -5.8%N/A9.3 $15.70 1/29/20212,930,000 shares $39.82 million +1.4%N/A10 $13.59 1/15/20212,890,000 shares $36.79 million +4.7%N/A9.8 $12.73 12/31/20202,760,000 shares $35.55 million +3.4%N/A10.4 $12.88 12/15/20202,670,000 shares $36.37 million -6.6%N/A10.4 $13.62 11/30/20202,860,000 shares $39.30 million -0.7%N/A10.8 $13.74 11/15/20202,880,000 shares $34.30 million +5.5%N/A10.3 $11.91 10/30/20202,730,000 shares $33.03 million +11.0%N/A10.3 $12.10 10/15/20202,460,000 shares $38.40 million -5.8%N/A9.3 $15.61 9/30/20202,610,000 shares $39.28 million +12.5%N/A9.9 $15.05 9/15/20202,320,000 shares $41.78 million +7.4%N/A7.5 $18.01 8/31/20202,160,000 shares $38.60 million -0.9%N/A6.6 $17.87 8/14/20202,180,000 shares $44.36 million +1.4%N/A7 $20.35 7/31/20202,150,000 shares $40.66 million +1.4%N/A6.3 $18.91 7/15/20202,120,000 shares $45.24 million +21.8%N/A5.9 $21.34 6/30/20201,740,000 shares $40.65 million +149.4%N/A4.7 $23.36 6/15/2020697,700 shares $19.19 million +12.2%N/A2 $27.50 5/29/2020622,000 shares $17.22 million -36.9%N/A1.9 $27.68 CUE Short Interest - Frequently Asked Questions What is Cue Biopharma's current short interest? Short interest is the volume of Cue Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 867,100 shares of CUE short. Learn More on Cue Biopharma's current short interest. What is a good short interest ratio for Cue Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CUE shares currently have a short interest ratio of 5.0. Learn More on Cue Biopharma's short interest ratio. Which institutional investors are shorting Cue Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cue Biopharma: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Cue Biopharma's short interest increasing or decreasing? Cue Biopharma saw a decline in short interest in April. As of April 30th, there was short interest totaling 867,100 shares, a decline of 1.8% from the previous total of 883,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Cue Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cue Biopharma: Voyager Therapeutics, Inc. (5.24%), Y-mAbs Therapeutics, Inc. (8.96%), Inventiva S.A. (0.75%), Cardiff Oncology, Inc. (26.28%), INmune Bio, Inc. (25.37%), Tiziana Life Sciences Ltd (1.32%), Molecular Partners AG (0.14%), Eledon Pharmaceuticals, Inc. (2.99%), CytomX Therapeutics, Inc. (12.08%), Organigram Holdings Inc. (8.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Cue Biopharma stock? Short selling CUE is an investing strategy that aims to generate trading profit from Cue Biopharma as its price is falling. CUE shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cue Biopharma? A short squeeze for Cue Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CUE, which in turn drives the price of the stock up even further. How often is Cue Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CUE, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies VYGR Short Squeeze YMAB Short Squeeze IVA Short Squeeze CRDF Short Squeeze INMB Short Squeeze TLSA Short Squeeze MOLN Short Squeeze ELDN Short Squeeze CTMX Short Squeeze OGI Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CUE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
